Skip to main content
. 2019 Jan 31;21(1):78–90. doi: 10.5853/jos.2018.02369

Table 1.

Study design and characteristics of included studies in our meta-analysis

Study Country Study design, registry No. of patients BP monitoring sICH definitions used Adjusted variables Outcomes
Ahmed et al. (2009) [22] Multinational Retrospective, SITS-ISTR (2002–2007) 11,080 Admission: 24 hr after IVT SITS-MOST Age, sex, weight, OTT, baseline NIHSS, glucose, and imaging, vascular risk factors, anti-HTN and antiplatelet medication, functional independence 2, 4*
Delgado-Mederos et al. (2008) [24] Spain Prospective 80 Admission: 24 hr after IVT - Baseline NIHSS, vascular risk factors, occlusion site, anti-HTN treatment 2, 5
Endo et al. (2013) [24] Japan Retrospective, SAMURAI rt-PA 527 Admission: 24 hr after IVT ECASS 2 Age, sex, baseline NIHSS, OTT, vascular risk factors, anti-HTN treatment prior to IVT, ASPECTS 1, 3, 4*
Huang et al. (2013) [25] China Retrospective 101 Admission: IVT ECASS 2 Baseline NIHSS and serum glucose, DM, leukoaraiosis 1
1*
Idicula et al. (2008) [26] Norway Prospective 127 Admission: 24 hr after IVT - Age, sex, baseline NIHSS, vascular risk factors 2*
Kellert et al. (2012) [27] Germany Retrospective 427 Admission: 24 hr after IVT ECASS 2 - 3
Kellert et al. (2017) [28] Multinational Prospective, SITS-ISTR (2002–2013) 16,434 Admission: 24 hr after IVT ECASS 2 SITS-MOST Age, sex, baseline NIHSS, vascular risk factors, SBP 1, 2, 3, 4*
Lindsberg et al. (2003) [29] Finland Retrospective 75 Admission: 24 hr after IVT - - 2
2*
Liu et al. (2016) [30] China Retrospective 461 Admission: 24 hr after IVT ECASS 2 Age, sex, baseline NIHSS, OTT, glucose, vascular risk factors 3
1, 3*
Martins et al. (2016) [31] Portugal Retrospective 674 Admission: 24 hr after IVT NINDS Age, sex, baseline NIHSS, Endovascular therapy, vascular risk factors, SBP 3*
Menon et al. (2012) [32] Multinational Prospective 10,242 Admission: 24 hr after IVT NINDS Age, sex, race, baseline NIHSS, SBP, glucose 3*
Molina et al. (2004) [33] Multinational Prospective, CLOTBUST 177 Admission: IVT ECASS 2 - 2
2*
Molina et al. (2009) [34] Multinational RCT, TUCSON 35 Admission: 36 hr after IVT SITS-MOST Age, sex, OTT, baseline NIHSS 1, 2, 3, 4, 5
1, 2, 4*
Rusanen et al. (2015) [35] Finland Retrospective 104 Admission: IVT - Age, sex, baseline NIHSS, OTT, vascular risk factors, occlusion site 2*
Saqqur et al. (2008) [36] Multinational Retrospective 349 Admission: 24 hr after IVT ECASS 3 Age, sex, baseline NIHSS, glucose, SBP, OTT 3
3*
Tomii et al. (2011) [37] Japan Prospective 125 Admission: 24 hr after IVT - Age, baseline NIHSS, vascular risk factors, eGFR 2*
Toni et al. (2012) [38] Italy Retrospective, SITS-ISTR (2002–2010) 3,246 Admission: 24 hr after IVT SITS-MOST Age, sex, baseline NIHSS, glucose, BP, OTT, vascular risk factors, functional independence 2, 3*
Tsivgoulis et al. (2007) [7] Multinational Retrospective, CLOTBUST 351 Admission: 2 hr after IVT ECASS 3 Age, sex, OTT, baseline NIHSS and serum glucose 1, 2, 3, 4, 5
1, 2, 3, 4, 5*
Tsivgoulis et al. (2009) [6] USA Retrospective 510 Admission: IVT ECASS 3 Age, sex, OTT, baseline NIHSS, vascular risk factors and medications 3
3*
Wahlgren et al. (2008) [8] Multinational Prospective, SITS-MOST (2002–2006) 6,483 Admission: IVT SITS-MOST Age, sex, weight, ASPECTS, baseline NIHSS and glucose, vascular risk factors and medications, SBP, functional independence 2, 3, 4*
Waltimo et al. (2016) [39] Finland Retrospective 1,868 Admission: 48 hr after IVT ECASS 2, NINDS, SITS-MOST Age, SBP, baseline NIHSS, glucose and ASPECTS 3*
Wu et al. (2017) [40] China Retrospective 420 Admission: IVT - Age, sex, BMI, baseline NIHSS, OTT, SBP, vascular risk factors 2
2*
Wu et al. (2016) [41] China Prospective, TIMS-CHINA 1,128 Admission: 24 hr after IVT NINDS Age, sex, baseline NIHSS, ASPECTS, OTT, aspirin use 1, 2, 3*
Yan et al. (2015) [42] China Retrospective 161 Admission: 2 hr after IVT ECASS 2 Vascular risk factors 5
Yong et al. (2005) [43] Multinational Post hoc RCT, ECASS 615 Admission: 72 hr after IVT - Age, sex, weight, baseline SSS, OTT, aspirin use, ASPECTS, vascular risk factors 1
Yong et al. (2008) [44] Multinational Post hoc RCT, ECASS 2 793 Admission: 24 hr after IVT - Age, sex, baseline SSS, OTT, aspirin use, ASPECTS, vascular risk factors 1, 4*

(1) Favorable functional outcome (modified Rankin Scale [mRS] 0–1), (2) functional independence (mRS 0–2), (3) sICH, (4) mortality, (5) recanalization.

BP, blood pressure; sICH, symptomatic intracranial hemorrhage; SITS-ISTR, Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register; IVT, intravenous thrombolysis; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; OTT, onset-to-treatment; NIHSS, National Institutes of Health Stroke Scale; HTN, hypertension; SAMURAI rt-PA, Stroke Acute Management with Urgent Risk-factor Assessment and Improvement recombinant tissue plasminogen activator; ECASS, European Cooperative Acute Stroke Study; ASPECTS, Alberta stroke program early CT score; DM, diabetes mellitus; SBP, systolic blood pressure; NINDS, National Institute of Neurological Disorders and Stroke; CLOTBUST, Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic tPA; RCT, randomized controlled trial; TUCSON, transcranial ultrasound in clinical sonothrombolysis; eGFR, estimated glomerular filtration rate; BMI, body mass index; TIMS-CHINA, thrombolysis implementation and monitor of acute ischemic stroke in China; SSS, Scandinavian Stroke Scale.

*

Adjusted multivariable data;

Unadjusted descriptive data.